RxDoctor Payments Data

Lauren Chaffey, PA

Medical · Depew, NYNPI 1700477957

Payments from drug & device makers

$4,025in general payments, 2019–2025

Across 209 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$593
  • AstraZeneca$446
  • Novo Nordisk$421
  • Lilly USA, LLC$326
  • Pfizer$297
  • Boehringer Ingelheim$285
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,025 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$11,466
Medicare patients
96
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$31,970
RybelsusSemaglutide13$29,223
EliquisApixaban13$17,318
Atorvastatin Calcium133$1,890
Rosuvastatin Calcium102$1,560
Levothyroxine Sodium94$1,523
Lisinopril97$1,060
Metoprolol Succinate50$975
Losartan Potassium54$947
Omeprazole54$922
SynthroidLevothyroxine Sodium14$784
Albuterol Sulfate HfaAlbuterol Sulfate22$760
Metformin Hcl46$706
Irbesartan15$681
Fluticasone Propionate31$676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$285$31,97025 claims
Novo NordiskRybelsus$421$29,22313 claims
PfizerEliquis$297$17,31813 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$1,52394 claims
AbbVieSynthroid$593$78414 claims
Almatica Pharma LLCSertraline Hcl$25$16914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.

Other medical in Depew

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →